CHICAGO, March 5, 2026, 14:11 CST
- AbbVie wrapped up a multi-tranche senior notes offering on March 4, according to a regulatory filing.
- The drugmaker said it plans to use the proceeds for near-term debt repayment and other corporate purposes.
- AbbVie shares slipped in afternoon trading.
AbbVie (ABBV.N) wrapped up its earlier $8 billion senior unsecured notes sale on March 4, according to a regulatory filing. Shares slipped roughly 2.6%, last seen trading at $229.98 in the afternoon.
This deal is a cash move for AbbVie, aimed at wiping out near-term debt instead of letting its bank borrowing deadline creep closer. In a related filing for the offering, AbbVie projected net proceeds around $7.95 billion. Most of that amount will go toward paying off a term loan maturing in May; any leftover funds head to general corporate uses, possibly covering more debt.
The deal comprises seven tranches, with maturities stretching all the way to 2066. One slice pays a floating rate—SOFR plus 48 basis points. The rest are fixed-rate notes, offering coupons between 3.775% and 5.650%. Lead underwriters include J.P. Morgan, BofA Securities, Morgan Stanley, and Wells Fargo.
AbbVie provided a closer look at its banking arrangements in the prospectus supplement. In April 2025, the company entered a $4.0 billion 364-day delayed draw term loan facility. Of that, $2.0 billion is already drawn, with the facility set to mature on May 11, 2026. Borrowings under this agreement are available at either a base rate or adjusted SOFR, each with an added margin. Separately, the same filing shows AbbVie has a $2.0 billion fixed-rate term loan due in April 2027.
AbbVie’s latest balance-sheet adjustments come as the market zeroes in on whether newer drugs will offset lost Humira sales amid ongoing biosimilar pressure. Skyrizi and Rinvoq are carrying much of the weight. Even so, a William Blair analyst highlighted mounting competition in the immunology segment, pointing to Johnson & Johnson’s Tremfya as one threat. CFO Scott Reents told investors, “We continue to expect low-single-digit pricing headwinds for both of those products, both in 26 and over the next few years as well.” Reuters
Deal-making hasn’t faded, either. AbbVie, having dropped more than $20 billion on acquisitions since 2023 to shore up its pipeline following Humira’s patent cliff, also struck a deal last year to acquire cell therapy player Capstan Therapeutics for as much as $2.1 billion. BMO analyst Evan Seigerman described the strategy as “building on dominance in the inflammatory space.” Reuters
AbbVie is funneling $380 million into expanding its North Chicago campus, planning to add two new facilities dedicated to active pharmaceutical ingredient production. Construction kicks off in spring 2026, with both buildings slated to come online by 2029. APIs, or active chemical ingredients in drugs, are the focus of this expansion.
Still, refinancing won’t erase the broader doubts dogging big pharma’s cash streams. AbbVie is battling the U.S. government in court, pushing back against efforts to bring Botox under Medicare drug price talks—a legal clash that could reveal the limits of pricing controls and the extent of the revenue squeeze on its aesthetics segment.
The bond deal buys AbbVie breathing room and extends its maturity schedule as it pushes to sustain immunology growth and hold the line on pricing in a market that’s only getting more competitive.
